Trends in rare disease drug development
In the words of FDA health science policy analyst Atasi Poddar , the FDA wants patients to know how important it is that clinical trial participants reflect the diversity of the people across our nation who will be taking the medication, if approved. By ensuring that underrepresented populations participate in studies, you can reduce health disparities that might have otherwise ruled out healthy volunteers
For patients addressing performance, recovery, and longevity simultaneously
Higher concentrations of free phospholipids in viral infections were consistent with disruption of host cell membranes, whereas the elevated short-chain acylcarnitines may reflect compromised mitochondrial homeostasis and energy generation
Keeping your blood sugar under control can help prevent kidney complications
Supplementary Video 2 (download MOV MpRALF1 peptide treatment promoted the motility of Mp ralf1 mutant sperm